TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04382742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dynamic Resistance Exercises
Description: Modified Wingate protocol that incorprates 20 minutes of training on a cycle ergometer; included one minute of cycling with resistance to be performed at 85% to 90% of Maximal Heart Rate (MHR) followed by one minute of cycling with no resistance. The protocol will be performed for 10 times for a duration of 20 minute of workout.
Study: NCT02487030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Tablets administered orally in a divided daily dose based on weight (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Tablets administered orally in a divided daily dose based on weight (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Tablets administered orally in a divided daily dose based on weight (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Tablets administered orally in a divided daily dose based on weight (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT00983385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol PR
Description: Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg Tapentadol PR twice daily, adjusted with 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed a dose of 500 mg of Tapentadol per day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation period
Description: Eligibility assessment period to characterize the baseline over a one week period (week -1). Participants continued their previous treatment prior to allocation to tapentadol, if eligible.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol PR
Description: Maintenance Period: In this period participants continued Tapentadol Prolonged Release (PR) on the dose established in the Titration and Optimal Dose Period. Tapentadol IR participants were not permitted to exceed a total daily tapentadol dose of 500 mg.
Study: NCT00189228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xolair
Description: Patients are administered Xolair
Study: NCT03960151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant
Description: Rolapitant 180mg PO, Days 1 and 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Palonosetron 0.25 mg IV, Days 1,3, and 5.
Study: NCT02092025

Intervention type: DRUG
Intervention: Azilsartan
Description: Azilsartan tablets
Study: NCT04689789

Intervention type: DIAGNOSTIC_TEST
Intervention: optical coherence tomography angiography
Description: optical coherence tomography aniography is a non-invasive, fast, diagnostic imaging technique that evaluates the retinal vascular network

Intervention type: DIAGNOSTIC_TEST
Intervention: optical coherence tomography angiography
Description: optical coherence tomography aniography is a non-invasive, fast, diagnostic imaging technique that evaluates the retinal vascular network

Intervention type: DIAGNOSTIC_TEST
Intervention: optical coherence tomography angiography
Description: optical coherence tomography aniography is a non-invasive, fast, diagnostic imaging technique that evaluates the retinal vascular network
Study: NCT02161055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin dose was selected in accordance with the Yale Insulin Infusion Protocol.~• Amount of insulin (u) = \[fasting blood glucose (mmol/L) × 18-100\] × 10 × body weight (kilogram) × 0.6 ÷ 1000 ÷ 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin dose was selected in accordance with the Yale Insulin Infusion Protocol.~• Amount of insulin (u) = \[fasting blood glucose (mmol/L) × 18-100\] × 10 × body weight (kilogram) × 0.6 ÷ 1000 ÷ 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin dose was selected in accordance with the Yale Insulin Infusion Protocol.~• Amount of insulin (u) = \[fasting blood glucose (mmol/L) × 18-100\] × 10 × body weight (kilogram) × 0.6 ÷ 1000 ÷ 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin dose was selected in accordance with the Yale Insulin Infusion Protocol.~• Amount of insulin (u) = \[fasting blood glucose (mmol/L) × 18-100\] × 10 × body weight (kilogram) × 0.6 ÷ 1000 ÷ 2
Study: NCT02361008

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEE-guided perventricular device closure without CBP
Description: Perventricular device closure through minithoracotomy under the TEE-guidance without CBP.The device is an eccentric occluder made by Shanghai Shape Memory Alloy Co.,Ltd in Shanghai,China

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery repair with CBP
Description: Traditional surgery repair under the CBP.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery repair with CBP
Description: Traditional surgery repair under the CBP.
Study: NCT04598412

Intervention type: OTHER
Intervention: No intervention
Description: Cross-sectional

Intervention type: OTHER
Intervention: No intervention
Description: Cross-sectional

Intervention type: OTHER
Intervention: No intervention
Description: Cross-sectional

Intervention type: OTHER
Intervention: No intervention
Description: Cross-sectional
Study: NCT03960151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine 10 mg PO PM, Days 2,3,4,5,6-8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg AM, Days 1,2 and 3
Study: NCT03152539

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRS
Study: NCT02457403

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ROTEM
Description: Assess coagulopathy with ROTEM device compared to conventional laboratory tests. ROTEM will be used on all patients, however, determination of blood products used will be based on patient's randomization group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROTEM
Description: Assess coagulopathy with ROTEM device compared to conventional laboratory tests. ROTEM will be used on all patients, however, determination of blood products used will be based on patient's randomization group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: Assess coagulopathy with conventional laboratory tests (PT/INR, Hemoglobin, Platelet count). Conventional laboratory tests will be obtained on all subjects, however, determination of blood products used will be based on patient's randomization group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Therapy
Description: Assess coagulopathy with conventional laboratory tests (PT/INR, Hemoglobin, Platelet count). Conventional laboratory tests will be obtained on all subjects, however, determination of blood products used will be based on patient's randomization group.
Study: NCT02759666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3162
Description: SHR3162 capsule(s) is administered orally QD.
Study: NCT04384965

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagPro X100 Stimulator, B70 Fluid-Cooled Coil
Description: Treatment will occur 8 times per treatment day (50 min pause between treatments). Each treatment session will consist of a single iTBS treatment, delivering 600 pulses of iTBS (bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz, with a duty cycle of 2 seconds on, 8 seconds off, over 60 cycles / \~3 minutes) at a target of 110% of the subject's resting MT.
Study: NCT04330742

Intervention type: DRUG
Intervention: lactated ringers
Description: the intervention is one liter fluid bag of lactated ringers which is routinely used as a fluid coload for spinal anesthesia. All patients will receive the same amount of fluids however this will be paused at various time points in order to perform the echocardiogram.

Intervention type: DRUG
Intervention: lactated ringers
Description: the intervention is one liter fluid bag of lactated ringers which is routinely used as a fluid coload for spinal anesthesia. All patients will receive the same amount of fluids however this will be paused at various time points in order to perform the echocardiogram.

Intervention type: DRUG
Intervention: lactated ringers
Description: the intervention is one liter fluid bag of lactated ringers which is routinely used as a fluid coload for spinal anesthesia. All patients will receive the same amount of fluids however this will be paused at various time points in order to perform the echocardiogram.

Intervention type: DRUG
Intervention: lactated ringers
Description: the intervention is one liter fluid bag of lactated ringers which is routinely used as a fluid coload for spinal anesthesia. All patients will receive the same amount of fluids however this will be paused at various time points in order to perform the echocardiogram.
Study: NCT01707901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-8539
Description: Treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01659684

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: standard intravenous immunoglobulin
Description: Human standard intravenous immunoglobulin (IVIG), 0.5 g/Kg of body weight, monthly after confirmation of primary gestational CMV infection
Study: NCT02333786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long-axis/in-plane US-guided arterial catheterization
Description: Cannulate the radial artery or posterior tibial artery of an infant of a preschool child putting the 24 gauge needle parallel to the ultrasound transducer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long-axis/in-plane US-guided arterial catheterization
Description: Cannulate the radial artery or posterior tibial artery of an infant of a preschool child putting the 24 gauge needle parallel to the ultrasound transducer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short-axis/out-of-plane US-guided arterial catheterization
Description: Cannulate the radial artery or posterior tibial artery of an infant or a preschool child putting the 24 gauge needle perpendicular to the ultrasound transducer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short-axis/out-of-plane US-guided arterial catheterization
Description: Cannulate the radial artery or posterior tibial artery of an infant or a preschool child putting the 24 gauge needle perpendicular to the ultrasound transducer.
Study: NCT01505816

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Multifocal Intraocular Lens (RAYNER M-FLEX T TORIC IOL)
Description: Multifocal IOL implantation
Study: NCT00900029

Intervention type: BIOLOGICAL
Intervention: No HP802 Treatment

Intervention type: OTHER
Intervention: No HP802 Vehicle Treatment
Study: NCT00129129

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine
Description: Primary phase: 3 IM doses Booster phase: 1 IM dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine
Description: Primary phase: 3 IM doses Booster phase: 1 IM dose
Study: NCT03117478

Intervention type: OTHER
Group type: OTHER
Intervention: Magneto-encephalography (MEG)
Description: Magneto-encephalography

Intervention type: OTHER
Group type: OTHER
Intervention: Magneto-encephalography (MEG)
Description: Magneto-encephalography

Intervention type: OTHER
Group type: OTHER
Intervention: Magneto-encephalography (MEG)
Description: Magneto-encephalography

Intervention type: OTHER
Group type: OTHER
Intervention: Magneto-encephalography (MEG)
Description: Magneto-encephalography

Intervention type: OTHER
Group type: OTHER
Intervention: Electro-encephalography (EEG)
Description: Electro-encephalography

Intervention type: OTHER
Group type: OTHER
Intervention: Electro-encephalography (EEG)
Description: Electro-encephalography

Intervention type: OTHER
Group type: OTHER
Intervention: Electro-encephalography (EEG)
Description: Electro-encephalography

Intervention type: OTHER
Group type: OTHER
Intervention: Electro-encephalography (EEG)
Description: Electro-encephalography
Study: NCT02269072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide
Description: Administered twice during the study by injection
Study: NCT03117478

Intervention type: OTHER
Group type: OTHER
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: Functional Magnetic Resonance Imaging

Intervention type: OTHER
Group type: OTHER
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: Functional Magnetic Resonance Imaging

Intervention type: OTHER
Group type: OTHER
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: Functional Magnetic Resonance Imaging

Intervention type: OTHER
Group type: OTHER
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: Functional Magnetic Resonance Imaging

Intervention type: OTHER
Group type: OTHER
Intervention: Anatomical Magnetic Resonance Imaging (aMRI)
Description: Anatomical Magnetic Resonance Imaging

Intervention type: OTHER
Group type: OTHER
Intervention: Anatomical Magnetic Resonance Imaging (aMRI)
Description: Anatomical Magnetic Resonance Imaging

Intervention type: OTHER
Group type: OTHER
Intervention: Anatomical Magnetic Resonance Imaging (aMRI)
Description: Anatomical Magnetic Resonance Imaging

Intervention type: OTHER
Group type: OTHER
Intervention: Anatomical Magnetic Resonance Imaging (aMRI)
Description: Anatomical Magnetic Resonance Imaging

Intervention type: OTHER
Group type: OTHER
Intervention: Meditation
Description: Meditation

Intervention type: OTHER
Group type: OTHER
Intervention: Meditation
Description: Meditation
Study: NCT01674777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral
Study: NCT00741442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA806
Description: Uricosuric agent for the treatment of gout

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA806
Description: Uricosuric agent for the treatment of gout

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo.
Study: NCT01808235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral Health Intervention
Description: The dental hygienist will assess the IMD's tooth brushing technique and will provide specific feedback on the tooth brushing technique, including areas of the dentition missed in brushing. The IMDs will be given a powered toothbrush that records time, date and duration of toothbrushing activity, along with the direction and extent of motion of the toothbrushing activity. In addition, use of interdental cleaning aids will be recommended. The dental hygienist will review the findings from the oral health evaluation with the IMDs and caregivers, and provide detailed feedback on treatment and prevention of the oral health conditions and symptoms. The dental hygienist or study coordinator will call subjects by telephone biweekly to monitor oral hygiene practices and to provide coaching, if needed. Oral hygiene technique assessments will be conducted again three months after the first visit, and once more three months later, at the end of the intervention.
Study: NCT03772665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emixustat
Description: Once daily oral tablet taken for 24 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily oral tablet taken for 24 months
Study: NCT02698150

Intervention type: DEVICE
Intervention: HERMES tablet
Description: Tablet, sensors and wearables for daily collection of clinical data
Study: NCT02269072

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anastrozole
Description: Daily pill for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Daily pill for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert cream otherwise identical to testosterone cream applied daily for two weeks
Study: NCT02784834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Study: NCT03217994

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gel HP
Description: gel of hygrogen peroxide for teeth bleaching

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gel HP
Description: gel of hygrogen peroxide for teeth bleaching
Study: NCT04596748

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Bacillus Subtilis, Bacillus Clausii, Bacillus Coagulans, Bacillus Indicus HU36, MCC 102

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo caps
Study: NCT05196555

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repair of cleft palate with intravelar veloplasty (IVVP)
Description: A triangular flap is designed comprising new epithelial tissue which will be turned over to help close the nasal mucosa. Using a single hook, the oral mucosa and gland layer is separated from the muscle layer. Dissection of the greater palatine nerve-vessel bundle. The anterior palatal flap is raised by a curved elevator. The closure of the nasal mucosa and muscle is completed. Dissection of Velo Palatine Levator begins from the posterior rim of muscle and 5 mm from the midline.
Study: NCT01185977

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: one-week single-blind PBO-lead-in phase, FLX 10 mg/d for 4 days then 20 mg/d of FLX thereafter

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One pill of PBO for 4 days then two pills of PBO thereafter
Study: NCT03615339

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Molkosan
Description: Twice daily (AM and PM) 20ml of fermented whey concentrate consumed diluted in 200ml water
Study: NCT02831933

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADV/HSV-tk
Description: Replication-defective recombinant adenovirus vector

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: Prodrug of the antiviral drug acyclovir

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Low-dose SBRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Fully human immunoglobulin (Ig) G4 anti-PD-1 monoclonal antibody
Study: NCT04358965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous tranexamic acid
Description: patients will be given a single bolus IV injection of 15 mg/kg of tranexamic acid (TXA) 20 minutes before surgical incision plus one vaginal placebo tablet 60 minutes before skin incision.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal misoprostol
Description: patients will be given one vaginal misoprostol tablet (200 mcg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
Study: NCT01613703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2952
Description: 1 mg to 200 mg QD at a single descending dose
Study: NCT01548508

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functionnal ElectroStimulation (FES)
Description: Functionnal ElectroStimulation on lower limbs, 1h per day, 5 days per 7, during 6 weeks

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: SHAM on lower limbs, 1h per day, 5 days per 7, during 6 weeks
Study: NCT02687100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone
Description: beclometasone, 0.8 mg of saline to a volume of 8 mL, three times through the line for suctioning above the cuff: a) after positioning the tube; b) at the arrival in the cardiac intensive care unit; c) just prior to start respiratory weaning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients will receive 8 mL of saline without any drug
Study: NCT01298661

Intervention type: OTHER
Group type: OTHER
Intervention: Six-minute Step Test
Description: The patients underwent a test where they need to step up and down a 20cm test during six minutes.
Study: NCT02990039

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling letter
Description: The intervention is based on the Health Action Process Approach. The first letter provides information on knowledge regarding sedentary time and physical activity as well as intervenes on self-efficacy depending on the mindset of participants (non-intender, intender, actor). The second letter focuses on benefits and barriers of physical activity as well as the role of social support for physical activity. In case of actional stage, the third letter intervenes on self-efficacy again and suggests action and coping planning. Otherwise, the letter includes ipsative feedback according to the second letter.